Received: 11 June 2021
Accepted: 14 September 2021
First Online: 15 October 2021
: Not applicable (service evaluation).
: MS receives consultancy from Kyowa Kirin International and grant funding from Roche Diagnostics. SS received research funding from IDS. RE receives consultancy funding from IDS, Sandoz, Nittobo, Samsung, Haoma Medica, CL Bio, Biocon, Amgen, Hindustan Unilever, Pharmacosmos, Takeda and Viking and grant funding from Nittobo, Roche, Pharmacosmos and Alexion. JSW Speaker's honoraria from Eli Lilly and Sandoz, grant funding from Alexion, donation of drug from Eli Lilly and Consilient for clinical studies, consulting fees from Mereo Biopharma. NP, LTU, ET and AK declare they have no conflict of interest.